Biocommunication in Cardio-Metabolism (BC2M), University of Montpellier, 34000 Montpellier, France.
Int J Mol Sci. 2023 Dec 27;25(1):382. doi: 10.3390/ijms25010382.
Fibrosis is a common feature of cardiovascular diseases and targets multiple organs, such as the heart and vessels. Endothelial to mesenchymal transition is a complex, vital process that occurs during embryonic formation and plays a crucial role in cardiac development. It is also a fundamental process implicated in cardiac fibrosis and repair, but also in other organs. Indeed, in numerous cardiovascular diseases, the endothelial-to-mesenchymal transition has been shown to be involved in the generation of fibroblasts that are able to produce extracellular matrix proteins such as type I collagen. This massive deposition results in tissue stiffening and organ dysfunction. To advance our understanding of this process for the development of new specific diagnostic and therapeutic strategies, it is essential to develop relevant cellular and animal models of this process. In this review, our aim was to gain an in-depth insight into existing in vitro and in vivo models of endothelial to mesenchymal transition in cardiovascular diseases with a focus on cardiac fibrosis. We discuss important parameters impacting endothelial to mesenchymal transition, and we give perspectives for the development of relevant models to decipher the underlying mechanisms and ultimately find new treatments specific to fibrosis happening in cardiovascular diseases.
纤维化是心血管疾病的常见特征,涉及多个器官,如心脏和血管。内皮细胞向间充质转化是一个复杂而重要的过程,发生在胚胎形成过程中,在心脏发育中起着关键作用。它也是心脏纤维化和修复的基本过程,但也涉及其他器官。事实上,在许多心血管疾病中,内皮细胞向间充质转化被认为参与了能够产生细胞外基质蛋白如 I 型胶原的成纤维细胞的产生。这种大量沉积导致组织变硬和器官功能障碍。为了深入了解这一过程,开发新的特定诊断和治疗策略,开发该过程的相关细胞和动物模型至关重要。在这篇综述中,我们的目的是深入了解心血管疾病中内皮细胞向间充质转化的现有体外和体内模型,重点是心脏纤维化。我们讨论了影响内皮细胞向间充质转化的重要参数,并为开发相关模型提供了展望,以阐明潜在机制,并最终找到针对心血管疾病中发生的纤维化的新的特异性治疗方法。
Life Sci. 2017-7-14
Stem Cell Investig. 2023-9-28
Nat Rev Cardiol. 2018-8
J Cardiovasc Pharmacol Ther. 2021-1
Int J Mol Sci. 2025-3-26
Cell. 2023-9-14
Antioxidants (Basel). 2023-5-7
Front Endocrinol (Lausanne). 2023
Clin Exp Pharmacol Physiol. 2023-6
Diabetol Metab Syndr. 2023-1-25